Application of Escherichia coli in screening of PBC drug targets
By identifying and utilizing the characteristic gene combination of Escherichia coli strain PBC-EC01, diagnostic biomarkers and therapeutic targets for primary biliary cholangitis were developed. This solves the problems of the inability to identify high-risk groups early and the lack of precise treatment in existing technologies, and enables early risk identification of PBC and improves treatment outcomes.
Patent Information
- Application Number
- CN202610883193.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-06-18
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-06-18
AI Technical Summary
Current technologies lack microbial biomarkers that can specifically identify high-risk individuals for primary biliary cholangitis, making it impossible to predict disease risk and treatment response early. Conventional antibiotic treatment does not consider strain specificity and intestinal-urinary tract shared characteristics, lacks precise intervention strategies targeting specific pathogens, and ursodeoxycholic acid treatment is ineffective.
By isolating and identifying the Escherichia coli strain PBC-EC01, which is common to both the intestine and urinary tract, from patients with primary biliary cholangitis complicated by urinary tract infection, we found that it carries a characteristic fimbrial antigen gene combination and a short-chain fatty acid degradation gene. We developed diagnostic biomarkers and therapeutic targets based on this strain and constructed animal models to screen drugs.
It provides new diagnostic biomarkers and therapeutic targets, enabling early identification of PBC risk, precision treatment, improved treatment response rates, and reduced disease activity.
Smart Images

Figure CN122405511B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of clinical medical technology, and in particular to the application of Escherichia coli in PBC drug target screening. Background Technology
[0002] Primary biliary cholangitis (PBC) is an immune-mediated chronic cholestatic liver disease characterized by progressive destruction of intrahepatic small bile ducts, positive antimitochondrial antibodies (AMA), and cholestasis, which can eventually progress to cirrhosis.
[0003] Epidemiological studies have clearly shown that urinary tract infection (UTI) caused by *Escherichia coli* is a significant risk factor for polycystic biliary tract infection (PBC), with the incidence of recurrent UTI in PBC patients being 2.06 times higher than in the control group. However, traditional views hold that the association between UTI and PBC only reflects infection-triggered nonspecific immune activation, lacking identification of specific pathogens and elucidation of their pathogenic mechanisms. In recent years, the "gut-hepatic axis" theory has revealed the core role of gut microbiota dysbiosis and bacterial translocation in the pathogenesis of PBC, but the specific microbial vectors connecting gut microbiota to UTI risk and the molecular mechanisms driving bile duct injury remain unclear.
[0004] However, currently, there is a lack of microbial biomarkers that can specifically identify high-risk individuals for PBC, making it impossible to predict disease risk and treatment response early. Secondly, for PBC patients with UTIs, there is a lack of precise intervention strategies targeting specific pathogens, and conventional antibiotic treatment does not consider strain specificity and shared intestinal-urinary tract characteristics. Thirdly, the microbial triggering factors of the PDC-E2 molecular mimicry theory are not yet clear, and there is a lack of verifiable pathogen-self-antigen cross-reaction models. Ursodeoxycholic acid (UDCA) is the only approved first-line treatment, but approximately 40% of patients do not respond well, highlighting the urgent need to develop new biomarkers and therapeutic targets to improve clinical efficacy and patient prognosis.
[0005] Therefore, this invention is proposed. Summary of the Invention
[0006] To address the aforementioned technical problems, this invention provides the application of *Escherichia coli* in screening drug targets for primary biliary cholangitis (PBC). By isolating and identifying the *E. coli* strain PBC-EC01, shared by the intestine and urinary tract, from patients with primary biliary cholangitis complicated by urinary tract infection, it was found that this strain carries a characteristic fimbrial antigen gene combination and a short-chain fatty acid degradation gene. Its colonization is associated with the production of anti-PDC-E2 antibodies and intestinal barrier disruption in patients. This invention develops novel diagnostic biomarkers and therapeutic targets based on characteristic urinary tract pathogenic *E. coli*, which has positive implications for the early identification, risk stratification, and precision treatment of PBC.
[0007] In order to achieve the objective of this invention, the following technical solution is adopted: This invention provides an Escherichia coli, wherein the Escherichia coli ( Escherichia coli PBC-EC01 is deposited at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCCNO: M 2026815, and deposit date April 27, 2026.
[0008] This invention provides the application of the above-mentioned Escherichia coli in drug target screening for primary biliary cholangitis.
[0009] This invention provides a biomarker for assisting in the diagnosis of primary biliary cholangitis, the biomarker being the aforementioned *Escherichia coli*.
[0010] This invention provides the application of the above-mentioned Escherichia coli in the preparation of products for the auxiliary diagnosis of primary biliary cholangitis.
[0011] This invention provides the application of the above-mentioned Escherichia coli in constructing an animal model of primary biliary cholangitis.
[0012] This invention provides a method for constructing an animal model of primary biliary cholangitis, comprising the following steps: Non-human mammals were pretreated with antibiotics, followed by induction with the aforementioned *E. coli*, resulting in the non-human mammals exhibiting at least one of the following characteristics: Positive anti-PDC-E2 antibody, increased biliary tract inflammation, impaired intestinal barrier function, bacterial translocation to the liver or mesenteric lymph nodes, or an increased proportion of dendritic cells in the mesenteric lymph nodes.
[0013] This invention provides a method for screening drug targets in primary biliary cholangitis, comprising the following steps: S1. An animal model was constructed using the method described above for constructing an animal model of primary biliary cholangitis. S2. Administer the drug to the animal model; S3. Detect indicators related to primary biliary cholangitis in animal models after drug administration and compare them with the control group without drug administration to screen for drugs with preventive or therapeutic effects.
[0014] Furthermore, the indicators associated with primary biliary cholangitis are selected from: serum anti-PDC-E2 antibody levels, liver Ishak pathological score, bile duct inflammation score, ileum or colon tissue damage score, expression levels of tight junction proteins ZO-1 or Occludin, and MHC II in mesenteric lymph nodes. + CD11c+ The proportion of dendritic cells and the colonization of Escherichia coli in the liver or mesenteric lymph nodes.
[0015] The present invention also provides a pharmaceutical composition for the prevention or treatment of primary biliary cholangitis, which can specifically inhibit the growth of the above-mentioned Escherichia coli; Alternatively, remove the active ingredients of the aforementioned Escherichia coli, as well as pharmaceutically acceptable carriers or excipients.
[0016] Furthermore, the active ingredient is selected from: antibiotics, bacteriophages, specific antibodies or their antigen-binding fragments targeting the Escherichia coli.
[0017] The present invention has the following technical effects: This invention isolates and identifies the Escherichia coli strain PBC-EC01, which is common to both the intestinal and urinary tract, from PBC patients with combined UTIs. The clonal identity of the strain is confirmed by multiple sequence alignment (MLSA), 16S rRNA sequencing and multiple sequence typing (MLST). It was found that the strain carries the characteristic type I fimbriae FimH gene, type II secretion system genes gspE / gspF and short chain fatty acid degradation genes atcA / atcB, which are novel liquid biopsy biomarkers and potential therapeutic targets for PBC.
[0018] Furthermore, it was confirmed that PBC-EC01 colonization was associated with higher liver function indicators (ALT, AST, ALP, GGT, TBil, DBil), higher immunoglobulin (IgG, IgM) levels, and significantly reduced UDCA treatment response rate (25.0% vs 78.5%), demonstrating its potential as a non-invasive diagnostic biomarker.
[0019] Furthermore, the PBC animal model constructed in this invention more closely resembles the "gut microbiota-triggered" pathogenesis process in clinical patients, and can be used to screen anti-PBC drugs or evaluate treatment strategies that target and eliminate this strain. Detection kits or drug combinations developed based on this strain hold promise for providing new avenues for early risk identification and precision treatment of PBC. Attached Figure Description
[0020] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0021] Figure 1 To confirm that its sequence type (ST type) conforms to the characteristics of urinary tract origin by comparing the sequences of 7 genes; Figure 2 : Multisite sequence typing results, where A is the screening flowchart; B shows that the serum ALT, ALP and GGT levels of C57BL / 6J mice were significantly increased after 8 weeks of PBC-EC01 gavage. Figure 3 PBC-EC01 promotes cholangitis in dnTGFBRII mice; where A represents the division of dnTGFBRII mice into PBS, K12, and PBC-EC01 groups for 8 weeks; B represents the serum anti-PDC-E2 levels of the three groups of mice at different gavage time points detected by Western blot; C represents the liver pathological scores of the three groups of mice; and D represents the CD19 levels observed by flow cytometry. + B cells and CD138 + Changes in plasma cells; E represents CD45 in the liver. + Cell ratio; Figure 4 : Fluorescence and pathological images, where A is bacteria and Escherichia coli FISH in the liver of dnTGFBRII mice; B is liver pathology of dnTGFBRII mice after gavage. Figure 5 Results of PBC-EC01 disrupting the intestinal barrier in dnTGFBRII mice: A shows that, compared with the PBS and K12 groups, the PBC-EC01 group showed intestinal mucosal damage, accompanied by inflammatory cell infiltration in the colon (left) and ileum (right); B shows that immunohistochemical staining showed decreased expression of tight junction protein in the intestine of PBC-EC01 mice; C shows the ileal damage score (left) and colonic damage score (right) of the three groups of mice; D shows the DNA expression of ileal bacteria (EUB338) and Escherichia coli (ECO1167) detected by fluorescence in situ hybridization (FISH), showing that bacteria and Escherichia coli invaded the mucosa in the ileum of the PBC-EC01 group. Figure 6 The results are from a flow cytometry sorting instrument. A represents changes in MLN DCs observed by flow cytometry; B represents MHC II in MLNs. + CD11C + Cell ratio; Figure 7 Oral gavage with PBC-EC01 induced AMA production and promoted cholangitis in mice; where A represents the feeding, rearing, and experimental procedures for C57BL / 6J mice; B represents the ELISA detection of serum anti-PDC-E2 IgM antibodies in the three groups of mice at different time points after gavage; C represents the Western blot detection of serum anti-PDC-E2 IgM antibodies in the three groups of mice at different time points after gavage; and D represents the changes in MLN DCs observed by flow cytometry. Figure 8Further validation of the induction of AMA production and promotion of cholangitis in mice by oral gavage with PBC-EC01. A shows the mRNA expression of ZO-1 and Occludin in the colon of C57BL / 6J mice; B shows HE staining of liver tissue from three groups of C57BL / 6J mice 8 months after modeling; scale bar = 200 μm. Figure 9 Mass spectrometry results of Escherichia coli PBC-EC01 proteomics; AC shows that various somatic and secretory proteins in Escherichia coli PBC-EC01 are significantly different from those in Escherichia coli K12 strain; DE shows the GO / KEGG functional enrichment analysis of somatic and secretory proteins, mainly focusing on outer membrane proteins, LPS, flagella, and various metabolite production and secretion-related functions. Detailed Implementation
[0022] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions of this invention will be clearly and completely described below. Obviously, the described embodiments are only a part of the embodiments of this invention, and not all of them. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0023] In a first aspect, the present invention provides an *Escherichia coli*, wherein the *Escherichia coli* (… Escherichia coli PBC-EC01 is deposited at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M 2026815 and deposit date of April 27, 2026.
[0024] Secondly, the present invention provides the application of the above-mentioned Escherichia coli in the screening of drug targets for primary biliary cholangitis.
[0025] Thirdly, the present invention provides a biomarker for assisting in the diagnosis of primary biliary cholangitis, the biomarker being the aforementioned *Escherichia coli*.
[0026] Fourthly, the present invention provides the application of the above-mentioned Escherichia coli in the preparation of products for the auxiliary diagnosis of primary biliary cholangitis.
[0027] Fifthly, the present invention provides the application of the above-mentioned Escherichia coli in constructing an animal model of primary biliary cholangitis.
[0028] Sixthly, the present invention provides a method for constructing the above-mentioned animal model of primary biliary cholangitis, comprising the following steps: Non-human mammals were pretreated with antibiotics, followed by induction with the aforementioned *E. coli*, resulting in the non-human mammals exhibiting at least one of the following characteristics: Positive anti-PDC-E2 antibody, increased biliary tract inflammation, impaired intestinal barrier function, bacterial translocation to the liver or mesenteric lymph nodes, or an increased proportion of dendritic cells in the mesenteric lymph nodes.
[0029] In a seventh aspect, the present invention provides a method for screening drug targets for primary biliary cholangitis, comprising the following steps: S1. An animal model was constructed using the method described above for constructing an animal model of primary biliary cholangitis. S2. Administer the drug to the animal model; S3. Detect indicators related to primary biliary cholangitis in animal models after drug administration and compare them with the control group without drug administration to screen for drugs with preventive or therapeutic effects.
[0030] In some embodiments, the indicators associated with primary biliary cholangitis are selected from: serum anti-PDC-E2 antibody levels, liver Ishak pathological score, bile duct inflammation score, ileum or colon tissue damage score, expression levels of tight junction proteins ZO-1 or Occludin, and MHC II in mesenteric lymph nodes. + CD11c + The proportion of dendritic cells and the colonization of Escherichia coli in the liver or mesenteric lymph nodes.
[0031] Eighthly, the present invention also provides a pharmaceutical composition for the prevention or treatment of primary biliary cholangitis, which can specifically inhibit the growth of the aforementioned Escherichia coli. Alternatively, the active ingredients of the aforementioned Escherichia coli, as well as pharmaceutically acceptable carriers or excipients, may be removed.
[0032] In some embodiments, the active ingredient is selected from antibiotics, bacteriophages, specific antibodies, or antigen-binding fragments thereof targeting the *Escherichia coli*.
[0033] The following is a detailed explanation using specific embodiments: Example 1: This strain was deposited on April 27, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, Wuhan, China, with accession number CCTCC NO: M 2026815. This *E. coli* strain ( Escherichia coli PBC-EC01 is referred to as PBC-EC01 in the following embodiments and accompanying drawings.
[0034] This embodiment identifies the common intestinal and urinary tract strain of *Escherichia coli* PBC-EC01 from PBC patients with combined UTI through bacterial isolation and culture, multi-site sequence alignment, and whole-genome sequencing, and analyzes its characteristic genomic markers. Figures 1-2 Compared with Escherichia coli K12, the expression levels of genes related to the degradation of short-chain fatty acids (SCFAs) (such as atcA and atcB) in Escherichia coli PBC-EC01 increased; genes related to type I fimbriae (represented by FimH) were significantly increased; and the expression of genes related to type II secretion systems (such as gspE and gspF) also showed an increasing trend.
[0035] (1) Research subjects and sample collection In this embodiment, 36 patients with primary urinary tract infection (PBC) diagnosed at the autoimmune liver disease outpatient clinic of a hospital in Tianjin from September 2024 to September 2025 (with patient consent) were included, of whom 8 had concurrent endogenous urinary tract infection (UTI). The diagnosis of PBC conformed to the 2018 American Association for the Study of Liver Diseases (AASLD) guidelines. The diagnostic criteria for UTI were dysuria, urgency, and frequency with or without suprapubic pain and hematuria, and a urine culture colony count ≥10. 5 CFU / ml. Clean-catch midstream urine and stool samples were collected from patients in the morning and sent to the laboratory for processing within 2 hours at 4°C.
[0036] (2) Bacterial isolation and preliminary identification Urine and fecal samples were inoculated onto MacConkey agar plates (Hopebio, Qingdao, China) and incubated at 37°C and 5% CO2 for 18–24 hours. Single colonies were picked and identified using a VITEK MS automated microbial mass spectrometry system (bioMérieux, Inc., France). Once confirmed as Escherichia coli, the colonies were stored in glycerol tubes at -80°C for later use.
[0037] (3) Multiple sequence alignment (MLSA) of fimbrial antigen genes Specific primer pairs were designed targeting 22 E. coli fimbrial antigen genes (Table 1). After extracting bacterial genomic DNA, each target gene fragment was amplified by PCR. The products were verified by 1.5% agarose gel electrophoresis and then sent for Sanger sequencing. When 2-3 strains of E. coli from the same patient's feces and urine showed 100% nucleotide homology at ≥18 fimbrial antigen gene loci, they were preliminarily identified as "the same strain" of E. coli. Through comparison, a representative strain was selected and named PBC-EC01, which showed 100% homology at all 22 gene loci between urinary and intestinal strains (Table 2).
[0038] Table 1: List of primers for 22 fimbrial-related genes
[0039] Table 2: Comparison of 16S rRNA sequences of Escherichia coli isolated from urine and feces (1-900 bases)
[0040] (4) Verification of Multi-site Sequence Typing (MLST) Seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA, recA) were selected for PCR amplification and sequencing. The sequences were uploaded to the PubMLST database (https: / / pubmlst.org / ) for alignment to confirm the sequence type (ST type). The results showed that strain PBC-EC01 was of type ST131, which is an internationally prevalent highly pathogenic uropathogenic Escherichia coli clonal complex carrying multidrug resistance genes and virulence factors, providing molecular evidence for its urinary tract origin. The genetic background analysis of the strain using these seven housekeeping genes is a commonly used technique in multilocus sequence typing (MLST). The combination of these seven housekeeping genes provides sufficient sequence polymorphism to distinguish different strains while avoiding the random bias that may arise from single-gene analysis. This is a common method in this field for bacterial typing, phylogenetic comparison, and phylogenetic analysis.
[0041] (5) Whole genome sequencing and characteristic gene analysis Genomic DNA was extracted from strain PBC-EC01 and the control strain K12, and Illumina sequencing libraries (350 bp insert) were constructed. Paired-end sequencing (2 × 150 bp) was performed on the HiSeq 4000 platform. After FastQC quality control, trimmomatic adapter removal, and low-quality sequencing, the raw data were assembled using SPAdes v3.15.0 and annotated using Prokka v1.14.6. Comparative genomics analysis revealed the following characteristic gene markers in strain PBC-EC01 compared to K12: Type I fimbrial gene cluster: upregulated expression of the fimH gene (based on proteomics results, see Example 5), conferring strong urothelial adhesion ability to the strain; Type II secretory system: gspE and gspF genes are significantly overexpressed, promoting the secretion of effector proteins and host cell invasion; Short-chain fatty acid degradation genes: upregulation of atcA and atcB genes mediates butyrate degradation and weakens the intestinal chemical barrier.
[0042] from Figure 1The results show that MLST analysis confirmed that strain PBC-EC01 is ST131, which is consistent with the characteristics of urinary tract pathogenic Escherichia coli; PCR typing of fimbrial antigen genes showed 100% consistency at 22 sites; the expression of short chain fatty acid degradation genes atcA / atcB was significantly higher than that of K12; and the virulence gene heatmap visually demonstrated the pathogenic characteristics of strain PBC-EC01.
[0043] Example 2: This embodiment uses retrospective clinical data analysis to verify the correlation between PBC-EC01 strain colonization and PBC, and to evaluate its clinical value as a diagnostic marker (Table 3).
[0044] (1) Clinical data collection and grouping Complete clinical data of 36 PBC patients were collected (with patient consent), including: demographics, liver function indicators (ALB, GLO, ALT, AST, ALP, GGT, TBIL, DBIL), immunoglobulins (IgG, IgM), autoantibodies (AMA, AMA-M2, anti-gp210), liver stiffness score (FibroScan), and response to UDCA treatment. Based on urine culture results, patients were divided into a UTI-positive group (n=8, 6 of whom were positive for PBC-EC01 strain) and a non-UTI group (n=28), and the differences in clinical characteristics between the two groups were compared.
[0045] (2) Assessment of response to UDCA treatment According to the Paris II criteria, UDCA treatment response was defined as a decrease in serum ALP to less than 1.5 times the upper limit of normal and normal total bilirubin levels after one year of treatment. Response rates were calculated for both groups, and Fisher's exact test was performed.
[0046] (3) Statistical analysis Statistical analysis was performed using SPSS 23.0 software. Normally distributed continuous data were expressed as mean ± standard deviation (mean ± SD), and independent samples t-tests were used for comparisons between groups. Non-normally distributed data were expressed as median (interquartile range) [M(Q1,Q3)], and the Mann-Whitney U test was used. Categorical data were analyzed using the chi-square test. 2 Use the Fisher's exact test or p < 0.05 to consider the difference statistically significant.
[0047] In this embodiment, the association analysis results between PBC-EC01 strain colonization and clinical characteristics of PBC patients are attached. Figures 4-5 As shown in Table 3. Patients with UTI and positive PBC-EC01 strain compared to patients without UTI (Table 3).
[0048] Table 3: Demographic and biochemical characteristics of PBC with / without UTI
[0049] Liver function indicators: ALT (52.9 vs 67.5 U / L, p=0.405), AST (39.7 vs 64.6 U / L, p=0.013), ALP (139.3 vs 276.5 U / L, p=0.002), GGT (119.2 vs 431.6 U / L, p=0.013), TBil (12.1 vs 17.5 μmol / L, p=0.028), and DBil (3.63 vs 8.3 μmol / L, p=0.016) were all significantly elevated; Immunoglobulins: IgG (1374.1 vs 1744.3 g / L, p=0.015) and IgM (278.8 vs 480.0 g / L, p=0.004) levels were significantly increased; Treatment response: The response rate to UDCA was significantly lower (25.0% vs 78.5%, p=0.009). Disease progression: Liver stiffness value (8.7 vs 13.5 kPa, p=0.087) and positive rate of anti-gp210 antibody (62.5% vs 39.2%, p=0.422) both showed an increasing trend.
[0050] The above results confirm that PBC-EC01 colonization is closely related to disease activity, immune activation, and poor treatment response in PBC patients, and has the potential to serve as a diagnostic biomarker and prognostic indicator.
[0051] Example 3: This embodiment uses a dnTGFBRII mouse model to verify the pathogenic effects of PBC-EC01 strain in inducing anti-PDC-E2 antibody production, disrupting the intestinal barrier, and aggravating cholangitis, and compares it with the standard strain K12. Figure 2-6 ).
[0052] (1) Laboratory animals and grouping The dnTGFBRII mouse model was provided by the team of Lian Zhexiong at South China University of Technology. Male heterozygous dnTGFBRII mice were crossed with female C57BL / 6J mice. Genotypes were identified by gel electrophoresis at 3-4 weeks of age to obtain female heterozygous dnTGFBRII mice. All mice were housed in an SPF environment at Tianjin Medical University, maintained at a constant temperature of 22±1℃, with a 12-hour light / dark cycle, and provided with a standard diet and free access to water.
[0053] Experimental grouping: dnTGFBRII mice were randomly divided into 3 groups (n=8 / group): PBS control group, K12 gavage group, and PBC-EC01 gavage group.
[0054] (2) Antibiotic clearance and bacterial gavage Mice were given a mixed antibiotic regimen of ampicillin (1 g / L), vancomycin (0.5 g / L), neomycin (1 g / L), and metronidazole (1 g / L) in drinking water for 7 days to eliminate their intestinal flora. Subsequently, they were administered PBS orally and K12 strain (10 g / L) orally. 9 CFU / time) or PBC-EC01 strain (10 9 CFU / time), once every 3 days, for 8 weeks.
[0055] (3) Serological testing and antibody monitoring Blood was collected from the tail vein before gavage (week 0), at 3, 5, and 8, and serum was separated. Anti-PDC-E2 IgG and IgM antibodies were detected using ELISA: 96-well plates were coated with recombinant human PDC-E2 protein (5 μg / mL), incubated at a 1:200 serum dilution, and developed with HRP-labeled anti-mouse IgG / IgM secondary antibody. OD values were read at 450 nm. Western blot validation: 20 μg of recombinant PDC-E2 protein was subjected to SDS-PAGE electrophoresis, transferred to a membrane, incubated at a 1:500 serum dilution, and visualized using chemiluminescence.
[0056] (4) Histopathological evaluation Mice were euthanized at 8 weeks of age, and liver, ileum, and colon tissues were collected. The tissues were fixed in 4% paraformaldehyde for 48 hours, embedded in paraffin, and serially sectioned at 4 μm. Hematoxylin and eosin (HE) staining was used to assess the Ishak score of the liver (inflammation and necrosis 0-18 points, fibrosis 0-6 points) and the intestinal tissue damage score (0-4 points). Immunohistochemistry was used to detect the expression of the intestinal tight junction protein ZO-1 (rabbit anti-ZO-1, 1:200, Abcam).
[0057] (5) Flow cytometry analysis Isolate mesenteric lymph node (MLN) mononuclear cells, stain for FITC-CD11c, PE-MHCII, and APC-CD45, and analyze dendritic cells (DCs, CD11c) using FlowJo software. + MHCII + )Proportion.
[0058] (6) Fluorescence in situ hybridization (FISH) After dewaxing, paraffin sections of liver and colon tissue were incubated overnight at 4°C with a hybridization solution (20% formamide, 0.9M NaCl, 20mM Tris-HCl, pH 7.2) using Cy3-labeled E. coli-specific probe (ECO1167) and FITC-labeled universal bacterial probe (EUB338), followed by DAPI counterstaining and observation of bacterial colonization under a fluorescence microscope.
[0059] In this embodiment, the animal experimental procedure and serological test results are attached. Figure 2-3 As shown in the diagram, the experimental design clearly illustrates the groupings and time points. Serum ELISA results showed that anti-PDC-E2 IgG antibodies were detected in PBC-EC01 group dnTGFBRII mice after 3 weeks of gavage, significantly higher than those in the PBS group (p<0.001) and K12 group (p<0.001), and antibody levels continued to increase over time, reaching a peak at 8 weeks (1.23±0.34). Western blot validation showed a specific band in the serum of PBC-EC01 group recognizing recombinant PDC-E2 protein. Liver pathological evaluation showed that the Ishak inflammation and necrosis score (p<0.001) and fibrosis score (p=0.002) of the PBC-EC01 group were significantly higher than those of the control group.
[0060] In this embodiment, the effects of the PBC-EC01 strain on the intestinal barrier and immune activation are shown in the attached figure. Figures 6-7 As shown in the figure. Histological damage scores of the ileum and colon were significantly higher in the PBC-EC01 group than in the PBS and K12 groups (p<0.001). Immunohistochemistry showed that ZO-1 expression was significantly decreased in the PBC-EC01 group. Flow cytometry analysis showed that the proportion of DCs in the MLN of the PBC-EC01 group was significantly increased (p<0.001). FISH detection confirmed the presence of E. coli-specific signals in the liver tissue of the PBC-EC01 group, while the control group was negative.
[0061] Example 4: This embodiment uses C57BL / 6J wild-type mice to verify the pathogenic potential of the PBC-EC01 strain in immune-normal hosts, further confirming its ability to disrupt autoimmune homeostasis. Figures 7-8 ).
[0062] (1) Experimental design and grouping Female SPF-grade C57BL / 6J mice (6-8 weeks old, Beijing Huafukang) were randomly divided into 3 groups (n=8 / group): PBS group, K12 group, and PBC-EC01 group. The antibiotic clearance and gavage protocol was the same as in Example 3.
[0063] (2) Detection indicators and methods The detection time points and methods for serum anti-PDC-E2 antibody (ELISA and Western blot), liver HE staining, colon tight junction protein mRNA expression (RT-qPCR primers: ZO-1; Occludin), and liver function indicators (ALT, ALP, GGT) were the same as in Example 3.
[0064] In this embodiment, the pathogenicity of the PBC-EC01 strain in wild-type mice is shown in the attached figure. Figure 9As shown. See the experimental design diagram. Figure 9 A. Notably, unlike dnTGFBRII mice, there was no significant difference in anti-PDC-E2 antibody levels between the PBC-EC01 group and the control group in C57BL / 6J wild-type mice after 3 weeks of gavage (p>0.05). However, after 5 weeks of gavage, the antibody level in the PBC-EC01 group significantly increased (p<0.001), and the difference further widened at 8 weeks. Figure 9 B- Figure 9 C). This time lag suggests that immunocompetent hosts require a longer antigen exposure and immune activation process. RT-qPCR showed significantly downregulated expression of colonic ZO-1 (p<0.001) and Occludin mRNA (p<0.001) in the PBC-EC01 group. At 8 weeks, liver function indicators showed significantly elevated ALT (p=0.001), ALP (p<0.001), and GGT (p=0.002) in the PBC-EC01 group. Liver HE staining showed inflammatory cell infiltration in the portal area and bile duct damage in the PBC-EC01 group.
[0065] Example 5: This study employed DIA quantitative proteomics analysis on *E. coli* strains PBC-EC01 and K12, identifying 2862 proteins, of which 840 were significantly differentially expressed (301 upregulated and 539 downregulated). Functional analysis revealed increased expression of multiple pathogenicity-related proteins in PBC-EC01, involving outer membrane proteins, flagella, and metabolic pathways. Notably, lipoic acid synthase (LipA) was significantly overexpressed, potentially enhancing lipoylation of target proteins such as PDC-E2 by increasing lipoic acid synthesis, thereby increasing self-antigenicity, rather than depending on protein expression levels. This suggests that PBC-EC01 may exert its pathogenicity through multiple mechanisms, including post-translational modifications. Figure 9 ).
[0066] In summary, this invention, through systematic clinical-basic-translational research, has for the first time identified the intestinal-urinary tract shared *Escherichia coli* strain PBC-EC01 as a specific diagnostic biomarker and therapeutic target for primary biliary cholangitis (PBC). This strain carries a characteristic fimbrial antigen gene combination and a short-chain fatty acid degradation gene, and its colonization is significantly correlated with disease activity and poor treatment response in patients. Animal experiments have confirmed that the PBC-EC01 strain can induce the production of anti-PDC-E2 autoantibodies, disrupt the intestinal barrier, and exacerbate biliary inflammation; its pathogenic mechanism involves PDC-E2 molecular mimicry. This invention provides a new strategy for the precise diagnosis, risk stratification, and targeted therapy of PBC.
[0067] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the technical solutions of the embodiments of the present invention.
Claims
1. An Escherichia coli, characterized in that, The Escherichia coli PBC-EC01 ( Escherichia coli PBC-EC01 is deposited at the China Center for Type Culture Collection (CCTCC) with accession number CCTCC NO: M 2026815 and deposit date of April 27, 2026.
2. The application of Escherichia coli as described in claim 1 in drug target screening for primary biliary cholangitis.
3. The application of *Escherichia coli* as described in claim 1 in constructing an animal model of primary biliary cholangitis, characterized in that... The animal in question is a mouse.
4. A method for constructing an animal model of primary biliary cholangitis, characterized in that, Includes the following steps: Mice were pretreated with antibiotics, followed by induction with *E. coli* as described in claim 1, resulting in mice exhibiting at least one of the following characteristics: Positive anti-PDC-E2 antibody, increased biliary tract inflammation, impaired intestinal barrier function, bacterial translocation to the liver or mesenteric lymph nodes, or an increased proportion of dendritic cells in the mesenteric lymph nodes.
5. A method for screening drug targets in primary biliary cholangitis, characterized in that, Includes the following steps: S1. An animal model is constructed using the method for constructing an animal model of primary biliary cholangitis as described in claim 4; S2. Administer the drug to the animal model; S3. Detect indicators related to primary biliary cholangitis in animal models after drug administration and compare them with the control group without drug administration to screen for drugs with therapeutic effects.
6. The method for screening drug targets in primary biliary cholangitis according to claim 5, characterized in that, The indicators associated with primary biliary cholangitis were selected from: serum anti-PDC-E2 antibody levels, liver Ishak pathological score, bile duct inflammation score, ileum or colon tissue damage score, expression levels of tight junction proteins ZO-1 or Occludin, and MHC II in mesenteric lymph nodes. + CD11c + The proportion of dendritic cells and the colonization of Escherichia coli in the liver or mesenteric lymph nodes.
Citation Information
Patent Citations
Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using same
CN102480932A
Method for modeling acute purulent cholangitis in experimental animals
RU2232430C1
